G. Mcinnes

发表

Hematocrit Predicts Long-Term Mortality in a Nonlinear and Sex-Specific Manner in Hypertensive Adults

A. Dominiczak, P. Jeemon, G. Lowe, 2012, Hypertension.

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri

R. Collins, M. Caulfield, M. Nieminen, 2005, The Lancet.

British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary

Morris J. Brown, B. Williams, J. Potter, 2004, BMJ : British Medical Journal.

Long-Term and Ultra Long–Term Blood Pressure Variability During Follow-Up and Mortality in 14 522 Patients With Hypertension

Peter Meredith, David Morrison, Sandosh Padmanabhan, 2013, Hypertension.

Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)

M. Caulfield, M. Nieminen, E. O’Brien, 2005, The Lancet.

Extract from :

J F Potter, P S Sever, B. Williams, 2009 .

Angiotensin II antagonists in systolic blood pressure control.

G. Mcinnes, 2001, Hospital medicine.

Antioxidants and hypertension: another false dawn?

G. Mcinnes, 2005, Journal of hypertension.

TREATMENT OF HYPERTENSION IN NEW FRONTIERS This symposium took place on 30 th August 2015 as a part of the European Society of Cardiology ( ESC ) Congress in London , UK Co-Chairs

Speakers, B. Williams, G. Mcinnes, 2015 .

Comparison of the efficacy of candesartan and losartan: a meta-analysis of trials in the treatment of hypertension

L. Murray, P. Meredith, G. Mcinnes, 2010, Journal of Human Hypertension.

Angiotensin-II receptor blockers: benefits beyond blood pressure reduction?

L. Ruilope, G. Mcinnes, M. Volpe, 2005, Journal of Human Hypertension.

Acetaminophen Use and Risk of Myocardial Infarction and Stroke in a Hypertensive Cohort

A. Dominiczak, R. Touyz, S. Padmanabhan, 2015, Hypertension.

Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial

J. Laragh, A. Zanchetti, J. Degaute, 2006, Journal of hypertension.

Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO

J. Connell, G. Mcinnes, I. Ford, 2010, Journal of hypertension.

Morbidity and mortality trials

G. Mcinnes, 2008 .

Antihypertensive Therapy Benefits: Pleiotropic Versus Blood Pressure-Dependent Mechanisms

S. Kjeldsen, G. Mcinnes, 2012 .

Debate: does it matter how you lower blood pressure?

G. Mcinnes, 2001, Current controlled trials in cardiovascular medicine.

Hypertension control – an old song resung

G. Mcinnes, 2004, Blood pressure.

University of Dundee Prevention And Treatment of Hypertension With Algorithm-based therapy ( PATHWAY ) number 2

D. Webb, M. Caulfield, Morris J. Brown, 2015 .

Long-Term Outcome following Attendance at a Transient Ischemic Attack Clinic

M. Walters, J. Dawson, G. Mcinnes, 2011, International journal of stroke : official journal of the International Stroke Society.

Telmisartan to prevent recurrent stroke: the PRoFESS study: was the baby thrown out with the bathwater?

G. Mcinnes, 2009, Stroke.

Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial.

R. Collins, M. Caulfield, E. O’Brien, 2006, European heart journal.

The Role of Olmesartan Medoxomil in the Management of Hypertension

M. Böhm, G. Mcinnes, T. Unger, 2012, Drugs.

The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial: Outcomes in Patients Receiving Monotherapy

J. Laragh, A. Zanchetti, S. Kjeldsen, 2006, Hypertension.

The expanding role of angiotensin receptor blockers in the management of the elderly hypertensive

G. Mcinnes, 2003, Current medical research and opinion.

Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia.

G. Jackson, G. Mcinnes, M. Mir, 1994, The American journal of medicine.

EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS (ESC)

G. Mcinnes, 2007 .

Self monitoring of triglyceride concentrations: Improvement not proved

G. Mcinnes, 1993 .

Acetaminophen use and change in blood pressure in a hypertensive population

A. Dominiczak, S. Padmanabhan, J. Hewitt, 2013, Journal of hypertension.

Microalbuminuria in subjects with hypertension attending specialist blood pressure clinics

J. Webster, S. Padmanabhan, G. Mcinnes, 2016, Journal of Human Hypertension.

2003 European Society of Hypertension-European Society of Cardiology Guidelines for the Management of Arterial Hypertension

S. Priori, G. Mancia, A. Zanchetti, 2003, Heart Drug.

The effect of antihypertensive agents in people at high risk of cardiovascular disease and diabetes: a view through smoke and mirrors

G. Mcinnes, 2011, Journal of Human Hypertension.

Olmesartan Medoxomil

G. Mcinnes, 2012, Drugs.

The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes

R. Collins, M. Caulfield, M. Nieminen, 2008, Journal of hypertension.

Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study

A. Zanchetti, L. Ruilope, S. Kjeldsen, 2001 .

Concentration-effect relationships for oxprenolol in patients with essential hypertension.

M. Brodie, G. Mcinnes, 1988, British journal of clinical pharmacology.

2003 European Society of Hypertension-European Society of Cardiology Guidelines for the Management of Arterial Hypertension

S. Priori, G. Mancia, A. Zanchetti, 2004, Heart Drug.

Debate: does it matter how you lower blood pressure?

G. Mcinnes, 2001, Current Controlled Trials in Cardiovascular Medicine.

Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: The VALUE trial

G. Mancia, A. Zanchetti, R. Schmieder, 2008, Blood pressure.

The Unintended Consequences of Clinical Trials Regulations

G. Mcinnes, D. Conway, T. Macdonald, 2009, PLoS medicine.

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial

R. Collins, M. Caulfield, M. Nieminen, 2003, The Lancet.

24-hour powerful blood pressure-lowering: is there a clinical need?

G. Mcinnes, 2008, Journal of the American Society of Hypertension : JASH.

Valsartan in the treatment of hypertension

S. Kjeldsen, G. Mcinnes, H. Brunner, 2005 .

Chapter 84 – Vasodilators

G. Mcinnes, 2007 .

Direct‐Acting Vasodilators

J. Cohn, G. Mcinnes, A. Shepherd, 2011, Journal of clinical hypertension.

Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension.

G. Mancia, A. Zanchetti, S. Kjeldsen, 2012, The American journal of cardiology.

Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin Receptor Blockers

A. Hughes, B. Williams, N. Poulter, 2006, Journal of the renin-angiotensin-aldosterone system : JRAAS.

Angiotensin II antagonism in clinical practice: experience with valsartan.

G. Mcinnes, 1999, Journal of cardiovascular pharmacology.

Comparison of single and combination diuretics on glucose tolerance (PATHWAY-3): protocol for a randomised double-blind trial in patients with essential hypertension

D. Webb, M. Caulfield, Morris J. Brown, 2015, BMJ Open.

VERAPAMIL POTENTIATES CARBAMAZEPINE NEUROTOXICITY: A CLINICALLY IMPORTANT INHIBITORY INTERACTION

M. Brodie, G. Mcinnes, G. Macphee, 1986, The Lancet.

Antihypertensive Effects and Tolerability of Candesartan Cilexetil in an Elderly Population

G. Mcinnes, J. Jonker, 2000, Blood pressure.

Exforge: ARB/CCB combination for better hypertension control

G. Mcinnes, S. Chaplin, 2007 .

Cardiovascular and heart failure safety profile of vildagliptin: a meta‐analysis of 17 000 patients

M. Stumvoll, G. Mcinnes, S. Del Prato, 2015, Diabetes, obesity & metabolism.

Cardiovascular responses to verapamil and propranolol in hypertensive patients.

J. Cleland, G. Mcinnes, I. Findlay, 1985, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

J. Laragh, A. Zanchetti, S. Kjeldsen, 2004, The Lancet.

Monotherapy versus dual therapy for the initial treatment of hypertension (PATHWAY-1): a randomised double-blind controlled trial

D. Webb, M. Caulfield, Morris J. Brown, 2015, BMJ Open.

2003 European Society of Hypertension-European Society of Cardiology Guidelines for the Management of Arterial Hypertension

S. Priori, G. Mancia, A. Zanchetti, 2003, Heart Drug.

Combination of verapamil and beta blockers in systemic hypertension.

J. Cleland, G. Mcinnes, I. Findlay, 1986, The American journal of cardiology.

Clinical Advantage of Valsartan

G. Mcinnes, 1999, Cardiology.

Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial

R. Collins, M. Caulfield, M. Nieminen, 2001, Journal of hypertension.

Do ace inhibitors reduce mortality in hypertensive patients

L. Murray, P. Meredith, G. Mcinnes, 1998 .

Role of ACE inhibitors in hypertension complicated by vascular disease.

G. Mcinnes, 1994, British heart journal.

Possible mechanisms of protective effect of ACE inhibitors on cerebral vessels in hypertension Mechanism Normalisation of cerebral vascular reserve Decrease in vascular hypertrophy Increase in external diameter Normalisation of : Endothelial function Vascular mechanisms Antiatherosclerotic effect :

G. Mcinnes, 2022 .

Delivery of care for hypertension.

S. McGhee, G. Mcinnes, Gordon T. McInnes, 1995, Journal of human hypertension.

Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial— Lipid Lowering Arm (ASCOT-LLA): A Multicentre Randomised Controlled Trial

R. Collins, M. Caulfield, M. Nieminen, 2012, Drugs.

Heart rate as a risk factor in cardiovascular disease

S. Padmanabhan, G. Mcinnes, I. Menown, 2010 .

Cancer risk of hypertensive patients taking calcium antagonists

L. Murray, P. Meredith, G. Mcinnes, 1998, Journal of hypertension.

Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).

R. Collins, M. Caulfield, M. Nieminen, 2005, Diabetes care.

Does the aldosterone: renin ratio predict the efficacy of spironolactone over bendroflumethiazide in hypertension? A clinical trial protocol for RENALDO (RENin-ALDOsterone) study

J. Connell, G. Mcinnes, I. Ford, 2007, BMC cardiovascular disorders.

Morbidity and mortality trials: black and white or shades of grey?

G. Mcinnes, 2009 .

Never mind the quality, feel the width – ALLHAT revisited

S. Kjeldsen, G. Mcinnes, 2004, Blood pressure.

How important is optimal blood pressure control?

G. Mcinnes, 2004, Clinical therapeutics.

ALLHAT: a saga of missed opportunities

G. Mcinnes, 2003, Journal of Human Hypertension.

Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?

L. Murray, P. Meredith, G. Mcinnes, 1998, The Lancet.

Drug Interactions that Matter

M. Brodie, G. Mcinnes, Martin J. Brodie, 1988, Drugs.

Carbamazepine and Haem Biosynthesis in Man

M. Brodie, G. Mcinnes, M. Moore, 1982 .

The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure.

R. Collins, M. Caulfield, M. Nieminen, 2008, European heart journal.

Acute adverse reactions attributed to allopurinol in hospitalised patients.

G. Mcinnes, H. Jick, D. Lawson, 1981, Annals of the rheumatic diseases.

Chlormethiazole and alcohol: a lethal cocktail.

G. Mcinnes, 1987, British medical journal.

Cardiac arrest following chlormethiazole infusion in chronic alcoholics.

G. Mcinnes, B. Avery, R. Young, 1980, Postgraduate medical journal.

Steady‐state relative potency of aldosterone antagonists: Spironolactone and prorenoate

G. Mcinnes, J. Shelton, I. Harrison, 1981, Clinical pharmacology and therapeutics.

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

Isla Mackenzie, Sandosh Padmanabhan, Bryan Williams, 2015, The Lancet.

Effects of a single moderate dose of alcohol on blood pressure, heart rate and associated metabolic and endocrine changes.

S G Ball, S. Ball, G. Mcinnes, 1987, Clinical science.

Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial

G. Mancia, A. Zanchetti, R. Schmieder, 2006, Journal of hypertension.

Overtime is bad for the heart.

G. Mcinnes, 2010, European heart journal.

Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist

J. Connell, G. Mcinnes, F. McManus, 2008, Nature Clinical Practice Endocrinology &Metabolism.

Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial

A. Zanchetti, R. Schmieder, S. Kjeldsen, 2008, Journal of hypertension.

Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study.

G. Mcinnes, B. Waeber, G. Leonetti, 1999, Journal of hypertension.

The value of therapeutic drug monitoring to the practising physician--an hypothesis in need of testing.

G. Mcinnes, 1989, British journal of clinical pharmacology.

The Effects of Spironolactone and Amiloride on Plasma Electrolytes in Thiazide Treated Subjects

G. Mcinnes, D. Davies, 1987 .

Dose‐response relationships for spironolactone in combination with a potassium‐wasting diuretic

G. Mcinnes, J. Clarke, J. Shelton, 1983, Clinical pharmacology and therapeutics.

Relative potency of amiloride and spironolactone in healthy man

G. Mcinnes, 1982, Clinical pharmacology and therapeutics.

Dose‐response relationships for spironolactone at steady state

G. Mcinnes, J. Shelton, I. Harrison, 1982, Clinical pharmacology and therapeutics.

Bioassay of a new aldosterone antagonist and evaluation of a simple method of quantitative comparison

G. Mcinnes, J. Clarke, J. Shelton, 1981, Clinical pharmacology and therapeutics.

Activity of sulfur‐containing intermediate metabolites of spironolactone

G. Mcinnes, J. Clarke, J. Shelton, 1980, Clinical pharmacology and therapeutics.

Serum Chloride Is an Independent Predictor of Mortality in Hypertensive Patients

Rajan K. Patel, A. Dominiczak, P. Jeemon, 2013, Hypertension.

Why not prescribe the best drugs for hypertension now?

G. Mcinnes, T. Macdonald, G. Mcinnes, 2003, Journal of Human Hypertension.

A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism

J. Connell, J. Ménard, L. Ruilope, 2011, Journal of hypertension.

Pre-hypertension: how low to go and do drugs have a role?

G. Mcinnes, 2012, British journal of clinical pharmacology.

Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial

J. Laragh, A. Zanchetti, S. Kjeldsen, 2004, The Lancet.

What is the true place of blood pressure in cardiovascular risk management?

G. Mcinnes, 2007, Journal of hypertension.

Lowering blood pressure for cardiovascular risk reduction

G. Mcinnes, 2005, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

Influence of a single dose of 20 mg tadalafil, a phosphodiesterase 5 inhibitor, on ambulatory blood pressure in subjects with hypertension.

G. Mcinnes, T. MacDonald, J. Webster, 2006, British journal of clinical pharmacology.

Effect of Area-Based Deprivation on the Severity, Subtype, and Outcome of Ischemic Stroke

G. Mcinnes, J. Reid, K. Lees, 2003, Stroke.

Resting Heart Rate Pattern During Follow-Up and Mortality in Hypertensive Patients

J. Connell, A. Dominiczak, S. Padmanabhan, 2010, Hypertension.

The VALUE Trial

J. Laragh, A. Zanchetti, S. Kjeldsen, 2005 .

Characteristics of 15314 Hypertensive Patients at High Coronary Risk. The VALUE Trial

J. Laragh, A. Zanchetti, S. Kjeldsen, 2001 .

Risks of socioeconomic deprivation on mortality in hypertensive patients

L. Murray, S. Padmanabhan, M. Walters, 2009, Journal of hypertension.

Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial

Sandosh Padmanabhan, Bryan Williams, D. Webb, 2016, The lancet. Diabetes & endocrinology.

Drug treatment of prehypertension: Not now, not ever?

G. Mcinnes, 2009, Blood pressure.

Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies

D. Webb, M. Caulfield, Morris J. Brown, 2018, The lancet. Diabetes & endocrinology.

VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk

J. Laragh, A. Zanchetti, S. Kjeldsen, 2003 .

Noninvasive Cardiac Event Monitoring to Detect Atrial Fibrillation After Ischemic Stroke: A Randomized, Controlled Trial

P. Macfarlane, P. Langhorne, P. Higgins, 2013, Stroke.

Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy

G. Mancia, A. Zanchetti, S. Kjeldsen, 2012, Journal of hypertension.

Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double‐Blind Randomized Controlled Trial

D. Webb, M. Caulfield, Morris J. Brown, 2017, Journal of the American Heart Association.

The differences between ACE inhibitor-treated and calcium channel blocker-treated hypertensive patients.

G. Mcinnes, 2003, Journal of clinical hypertension.

Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial

A. Zanchetti, L. Ruilope, J. Segura, 2007, Journal of hypertension.

Systolic Hypertension as a Cardiovascular Risk Factor

G. Mcinnes, 2002, Blood pressure.

Contrasting mortality risks among subgroups of treated hypertensive patients developing new-onset diabetes.

A. Dominiczak, P. Jeemon, S. Padmanabhan, 2016, European heart journal.

Special management needs of the elderly hypertensive patient

G. Mcinnes, H. Elliott, 2002 .

Special management needs of the elderly hypertensive patient

G. Mcinnes, H. Elliott, 2002, Journal of the renin-angiotensin-aldosterone system : JRAAS.

Blood Pressure Response to Patterns of Weather Fluctuations and Effect on Mortality

A. Dominiczak, P. Jeemon, S. Padmanabhan, 2012, Hypertension.

VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk.

J. Laragh, A. Zanchetti, S. Kjeldsen, 2004, American journal of hypertension.

Size isn't everything--ALLHAT in perspective.

G. Mcinnes, 2003, Journal of hypertension.

Trends in psychotropic prescribing in general practice and general medical patients.

G. Mcinnes, A. Smith, D. Lawson, 1986, Postgraduate medical journal.

hospitalised patients . attributed to allopurinol in Acute adverse reactions

G. Mcinnes, H. Jick, D. Lawson, 2022 .

Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial

Morris J. Brown, G. Mcinnes, T. MacDonald, 2011, The Lancet.

Prevention And Treatment of Hypertension With Algorithm-based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug-resistant hypertension

D. Webb, M. Caulfield, Morris J. Brown, 2015, BMJ Open.

Integrated approaches to management of hypertension: promoting treatment acceptance.

G. Mcinnes, 1999, American heart journal.

Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE trial. The Valsartan Antihypertensive Long-term Use Evaluation.

J. Laragh, A. Zanchetti, S. Kjeldsen, 2001, Blood pressure.

Serum Uric Acid Level, Longitudinal Blood Pressure, Renal Function, and Long-Term Mortality in Treated Hypertensive Patients

A. Dominiczak, P. Jeemon, S. Padmanabhan, 2013, Hypertension.

Clinical pharmacology and therapeutics of hypertension

G. Mcinnes, 2008 .

Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study

A. Zanchetti, L. Ruilope, S. Kjeldsen, 2001, Journal of hypertension.

The UK's NHS and pharma: need for more clinical pharmacologists

D. Webb, T. Walley, A. Breckenridge, 2009, The Lancet.

Hypertension: investigation, assessment and diagnosis.

G. Mcinnes, P. Semple, 1994, British medical bulletin.

Lack of effect of spironolactone on hair shaft diameter in hirsute females.

G. Mcinnes, A. Mclellan, J. Rentoul, 1989, Postgraduate medical journal.

Celiprolol and verapamil in the treatment of essential hypertension.

G. Mcinnes, A. Herrick, H. Dargie, 1988, American Heart Journal.

Cardiotoxicity and diuretics: much speculation--little substance.

G. Mcinnes, L. Ramsay, W. W. Yeo, 1992, Journal of hypertension.

Hemodynamic effects of a single moderate dose of alcohol in elderly subjects.

G. Mcinnes, B. O. Williams, G. Murray, 1991, Journal of studies on alcohol.

Angiotensin-receptor blockade, cancer, and concerns.

P. Meredith, G. Mcinnes, 2010, The Lancet. Oncology.

On-Line Supplement Serum Uric Acid Level , Longitudinal Blood Pressure , Renal Function and Long-term Mortality in Treated Hypertensive Patients

A. Dominiczak, P. Jeemon, S. Padmanabhan, 2013 .

Effect of Micronization on the Bioavailability and Pharmacologic Activity of Spironolactone

G. Mcinnes, J. Shelton, L. Ramsay, 1982, Journal of clinical pharmacology.

Chapter 36 – Critical Assessment of Hypertension Guidelines

G. Mcinnes, 2005 .

Response to Effect of serum chloride on mortality in hypertensive patients.

A. Dominiczak, P. Jeemon, S. Padmanabhan, 2014, Hypertension.

The Performance of Clinics for Out-Patient Control of Anticoagulation

G. Mcinnes, G. Mcinnes, G. Helenglass, 1987, Journal of the Royal College of Physicians of London.

2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension.

S. Priori, A. Zanchetti, J. Staessen, 2003, Journal of hypertension.

Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rationale and outline protocol

R. Collins, M. Caulfield, M. Nieminen, 2001, Journal of Human Hypertension.

Blood Pressure Response to Patterns of Weather Fluctuations and Effect on Mortality

Rajan K. Patel, A. Dominiczak, P. Jeemon, 2013, Hypertension.

British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary

Morris J. Brown, B. Williams, J. Potter, 2004, BMJ : British Medical Journal.

Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004—BHS IV

P. Sever, G. Mcinnes, J. Potter, 2004, Journal of Human Hypertension.

Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial

J. Laragh, A. Zanchetti, S. Kjeldsen, 2004, The Lancet.

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

M. Caulfield, B. Williams, S. Padmanabhan, 2015, The Lancet.

Expression of concern

J. Laragh, A. Zanchetti, S. Kjeldsen, 2018, Expert review of endocrinology & metabolism.

The effects of KT3-671, a new angiotensin II (AT 1) receptor blocker in mild to moderate hypertension.

G. Mcinnes, J. Webster, D. Patterson, 2003, British journal of clinical pharmacology.